BioSpace News Archive

The American Association of Kidney Patients announced that given the serious threat posed by the Coronavirus to the kidney patient community, they are encouraging all patients and their families to avoid unnecessary travel, including all planned travel to Washington, D.C. during National Kidney Month in March and for the immediate future.

Spherix Incorporated provided an update on the recently announced treatment for Coronavirus technology optioned by the Company.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1b trial evaluating the company’s investigational toll-like receptor 7 (TLR7) agonist vesatolimod as part of a human immunodeficiency virus (HIV) cure research program. These finding

The coronavirus pandemic shows the effect of government interference with free-market solutions, states the Association of American Physicians and Surgeons (AAPS). Testing is widely available in South Korea, which has more of a free market, while testing remains mostly unavailable in the United States. Convenient drive-through testing in South Korea has enabled it to react quickly and effectively to an ominous outbreak there. But for week

Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2019. Loss from operations for the three months and year ended December 31, 2019 was $5.4 million and $23.3 million.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the quarter and full year ended December 31, 2019 and summarized recent business results. “

Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its fourth quarter and full year ended December 31, 2019.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent corporate highlights.

TOMI Environmental Solutions, Inc.®, is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide.